Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Eisen

Showing results (11-20 of 116) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Targeting multiple kinase pathways: a change in paradigmLucy Gossage, Tim Eisen
Nature Reviews. Clinical Oncology|April 7, 2010
Alterations in VHL as potential biomarkers in renal-cell carcinomaLucy Gossage, Tim Eisen
Therapeutic Advances in Medical Oncology|November 2, 2013
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell cancer: latest results and clinical implicationsShahzeena Aslam, Tim Eisen
Expert Review of Anticancer Therapy|June 19, 2013
Tivozanib for the treatment of metastatic renal cancerHan Hsi Wong, Tim Eisen
BJU International|April 20, 2007
Prognostic factors in renal cell cancerWon-Ho Park, Tim Eisen
Therapeutics and Clinical Risk Management|March 25, 2008
Renal cell carcinoma and the use of sorafenibJames Mg Larkin, Tim Eisen
Expert Review of Anticancer Therapy|November 26, 2011
Finding needles in a haystack: annual low-dose computed tomography screening reduces lung cancer mortality in a high-risk groupSimon L Duke, Tim Eisen
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Her2-targeted therapies in non-small cell lung cancerCharles Swanton, Andy Futreal, Tim Eisen
Critical Reviews in Oncology/Hematology|July 25, 2006
Kinase inhibitors in the treatment of renal cell carcinomaJames M G Larkin, Tim Eisen
The Oncologist|January 17, 2009
Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor eraSwethajit Biswas, John Kelly, Tim Eisen
Pageof 12

Showing results (11-20 of 116) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Targeting multiple kinase pathways: a change in paradigmLucy Gossage, Tim Eisen
Nature Reviews. Clinical Oncology|April 7, 2010
Alterations in VHL as potential biomarkers in renal-cell carcinomaLucy Gossage, Tim Eisen
Therapeutic Advances in Medical Oncology|November 2, 2013
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell cancer: latest results and clinical implicationsShahzeena Aslam, Tim Eisen
Expert Review of Anticancer Therapy|June 19, 2013
Tivozanib for the treatment of metastatic renal cancerHan Hsi Wong, Tim Eisen
BJU International|April 20, 2007
Prognostic factors in renal cell cancerWon-Ho Park, Tim Eisen
Therapeutics and Clinical Risk Management|March 25, 2008
Renal cell carcinoma and the use of sorafenibJames Mg Larkin, Tim Eisen
Expert Review of Anticancer Therapy|November 26, 2011
Finding needles in a haystack: annual low-dose computed tomography screening reduces lung cancer mortality in a high-risk groupSimon L Duke, Tim Eisen
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Her2-targeted therapies in non-small cell lung cancerCharles Swanton, Andy Futreal, Tim Eisen
Critical Reviews in Oncology/Hematology|July 25, 2006
Kinase inhibitors in the treatment of renal cell carcinomaJames M G Larkin, Tim Eisen
The Oncologist|January 17, 2009
Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor eraSwethajit Biswas, John Kelly, Tim Eisen
Pageof 12